Results 121 to 130 of about 58,085 (295)
Circulating MicroRNAs in Elderly Type 2 Diabetic Patients [PDF]
, 2018 The circulating microRNAs (miRNAs) associated with type 2 diabetes (T2D) in elderly patients are still being defined. To identify novel miRNA biomarker candidates for monitoring responses to sitagliptin in such patients, we prospectively studied 40 T2D ...
Abballe, Luana +10 more
core +3 more sources
Journal of Diabetes Investigation, 2016 Omarigliptin is a novel, potent, long‐acting oral dipeptidyl peptidase‐4 inhibitor being developed as a once‐weekly (q.w.) treatment for type 2 diabetes mellitus patients, with 25 mg and 12.5 mg tablets recently being approved as market formulations in ...
Saori Tsuchiya +7 more
semanticscholar +1 more source
[Nonglycemic effects of dipeptidyl peptidase-4 inhibitors].
Terapevticheskii arkhiv, 2013 The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class.
A S Ametov, L L Kamynina
openaire +2 more sources
Dipeptidyl Peptidase 4 Inhibitors: Therapeutic Options
Effective PharmacotherapyDipeptidyl peptidase 4 inhibitors are a new innovative class of glucose-lowering drugs. The drugs belong to the group of incretin mimetics, prolonging the action of their own incretins. Since 2007, the list of proposed dipeptidyl peptidase 4 inhibitors has expanded significantly and significant experience in their use has accumulated.
S.V. Podachina, I.V. Soloviova
openaire +1 more source
Analgesic and anti-inflammatory effectiveness of sitagliptin and vildagliptin in mice [PDF]
, 2021 Cayasso, Mayella +6 more
core +1 more source
Health economic evaluation of dipeptidyl peptidase-4 inhibitors
Indian Journal of Endocrinology and Metabolism, 2011 Sir, The predicted loss of national income from diabetes in India is 336.6 billion International Dollars.[1] Furthermore, studies have demonstrated that the prevalence of diabetes in India is rising with the progression of time.[2] Therefore, this financial burden is bound to increase.
openaire +3 more sources
Sulphostin-inspired N-phosphonopiperidones as selective covalent DPP8 and DPP9 inhibitors
Nature CommunicationsCovalent chemical probes and drugs combine unique pharmacologic properties with the availability of straightforward compound profiling technologies via chemoproteomic platforms.
Leonard Sewald +12 more
doaj +1 more source
Effect of Saxagliptin, a Dipeptidyl Peptidase 4 Inhibitor, on Non-Alcoholic Fatty Liver Disease
Diabetes, Metabolic Syndrome and Obesity, 2020 Lin Chen,1,* Xiujuan Zhang,2,* Li Zhang,3 Dongmei Zheng2 1Department of Breast and Thyroid Surgery, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, People’s Republic of China; 2Department of ...
Chen L, Zhang X, Zhang L, Zheng D
doaj
Hydrolytic Metabolism of Cyanopyrrolidine DPP-4 Inhibitors Mediated by Dipeptidyl Peptidases [PDF]
, 2018 Fandi Kong +6 more
openalex +1 more source
Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
Indian Journal of Endocrinology and Metabolism, 2014 The pharmacological actions of the glucagon-like peptide-1 receptor agonists (GLP-1RA) are largely predictable as they interact directly with GLP-1 receptors on beta cells to mediate their glucose lowering effects by increasing GLP-1 in pharmacological range and not at all dependent upon endogenous GLP-1 secretion. The mechanism of action of dipeptidyl
openaire +3 more sources